FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readoutPhase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of Share XRoche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readouthttps://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/
AstraZeneca bags Imfinzi okay in big Chinese lung cancer marketChina has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the Share XAstraZeneca bags Imfinzi okay in big Chinese lung cancer markethttps://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/
FDA gives Roche’s Actemra emergency okay for severe COVIDRoche has been granted emergency approval by the FDA for its arthritis drug Actemra as a treatment for Share XFDA gives Roche’s Actemra emergency okay for severe COVIDhttps://pharmaphorum.com/news/fda-gives-roches-actemra-emergency-okay-for-severe-covid/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient groupNICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, Share XNICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient grouphttps://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/
Roche’s Tecentriq gets fourth European NSCLC indicationRoche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of Share XRoche’s Tecentriq gets fourth European NSCLC indicationhttps://pharmaphorum.com/news/roches-tecentriq-gets-fourth-european-lung-cancer-indication/
FDA looks at pulling speedy approvals for three cancer drugsFDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see Share XFDA looks at pulling speedy approvals for three cancer drugshttps://pharmaphorum.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs/
